Aug 13, 2026 08:00AM
Aug 5, 2026 09:07AM
Aug 5, 2026 08:00AM
Aug 2, 2026 07:30PM
Aug 2, 2026 07:30PM
May 31, 2026 07:30PM
May 12, 2026 08:00AM Ascentage Pharma to Participate in Three Upcoming Investor Conferences
Feb 9, 2026 08:00AM
Feb 5, 2026 06:30PM
Feb 5, 2026 06:30PM
Jan 14, 2026 08:25PM
Dec 17, 2025 08:00AM
Dec 8, 2025 07:45PM
Dec 8, 2025 07:45PM ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
Dec 8, 2025 07:45PM
Dec 7, 2025 08:10PM
Dec 6, 2025 10:15AM
Dec 4, 2025 07:00PM
Dec 1, 2025 08:00AM
Nov 24, 2025 07:00PM
Nov 19, 2025 08:00AM Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
Nov 3, 2025 08:10PM
Nov 3, 2025 08:10PM
Oct 29, 2025 08:00PM
Oct 7, 2025 08:00AM
Aug 25, 2025 08:00AM
Aug 20, 2025 07:57PM
Aug 17, 2025 07:30PM Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
Aug 1, 2025 08:00AM
Jul 23, 2025 08:00AM
Jul 17, 2025 04:30AM
Jul 14, 2025 10:36AM
Jul 14, 2025 10:35AM
Jul 14, 2025 05:23AM
Jul 10, 2025 09:30AM Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
Jul 7, 2025 07:30PM
Jun 15, 2025 07:30PM
Jun 9, 2025 07:30PM
Jun 2, 2025 07:30PM
Jun 2, 2025 07:30PM
May 22, 2025 08:15PM
Apr 23, 2025 07:00PM Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
Apr 21, 2025 07:00AM
Mar 25, 2025 07:00PM
Feb 7, 2025 08:24AM
Jan 23, 2025 06:41PM
Aug 22, 2024 11:34AM
Jun 23, 2024 08:15PM
Nov 29, 2021 06:01AM Ascentage Pharma Appoints Mr. Yiqing Chen as Chief Financial Officer

125,724 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All